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Background
•

Case

Congenital Generalized Lipodystrophy (CGL) is characterized by

•

widespread fat loss and severe metabolic abnormalities (1)
•

Day 1: Started on detemir 1.0 units/kg/day (titrated to a

•

Metreleptin, a synthetic leptin analog, is shown to decrease

•

Metformin use in infants has only been described in a few case

•

1 month follow up: Started on subcutaneous metreleptin

•

maximum dose of 4.4 units/kg/day)

gain, hyperphagia, and abdominal distension at a well child check

fasting triglycerides, fasting glucose, and HbA1c (2)

•

2-month-old SGA term female was noted to have poor weight

Clinical Course
and glargine discontinued

3 month follow up: Triglycerides improved, normal LFTs,

She was admitted for failure to thrive with weight z-score of -2.17

•

Day 3: Started on metformin suspension 50 mg/kg/day

and length z-score of -0.15

•

Day 4: Triglycerides, glucoses, and LFTs decreased (Table 1)

and normal glucoses while on 0.056 mg/kg/day of

Initial labs were notable for triglycerides 5,167 mg/dL, blood

•

Discharged home on glargine 0.7 units/kg/day (insurance

subcutaneous metreleptin and metformin

reports of CGL and Donohue syndrome (3) (insulin receptor

glucose 324 mg/dL, ALT 212 units/L, AST 215 units/L, elevated

mutation), and there is no established dosing for this age group

random insulin level of 257 mcIU/mL, and HbA1c 8.9% (Table 1)

denied detemir) and metformin

•

She had improved growth and met all developmental

•

milestones

Genetic evaluation revealed that she was homozygous for a

•

pathogenic variant in the AGPAT2 gene

Conclusion

Labs
Day 1

Day 4

3
months

Triglycerides (mg/dL)

5,167

758

229

HDL (mg/dL)

10

-

-

Glucose (mg/dL)

324

113-138

62-114

HgbA1c (%)

8.9

-

-

Insulin (mcIU/mL)

257

-

-

AST (units/L)

215

119

51

ALT (units/L)

212

124

48

Leptin (ng/mL)

0.3

-

-

Adiponectin (mcg/mL)

<0.2

-

-

Bicarbonate (mmol/L)

17

-

-

Table 1

•

•

Leptin is important in regulation of lipid and glucose
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